Navigating key mutations in RBD and SARS-CoV-2 epitope classification: Enhancing antibody therapeutic development amidst evolving challenges
Asia-Pacific Journal of Molecular Biology and Biotechnology · 20.06.2026 · 12
DOI: 10.35118/apjmbb.2026.034.2.02 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Molecular Biology and Biotechnology, online erschienen am 20.06.2026. Verfasst von Kelven Alexsius und 5 weiteren Autor:innen. Die Arbeit nennt 138 Literaturangaben.
Abstract (Originalsprache)
Mutations within the receptor‑binding domain (RBD) of SARS‑CoV‑2 present significant challenges to the development of vaccines and antibody‑based therapies. These alterations enable the virus to evade neutralizing antibodies produced by vaccination and also therapeutic antibodies currently in use. Research has further demonstrated that the RBD plays a critical role in mediating interactions with host cells and can alternate between two conformational states, referred to as “up” and “down.” In light of these challenges and the urgent need for effective countermeasures against emerging variants, the characterization and design of novel antibody formats are essential. This study aims to examine how RBD mutations and epitope classification can inform the advancement of antibody therapeutics, particularly in the context of ongoing viral evolution. Based on the data analysis, key mutations such as E484 and N501, together with the conserved epitope sequence 469STEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYR509, are proposed as promising targets for the development of antibody‑based therapies and vaccine strategies.
Zitieren
APA
Alexsius, K., Amin, I. M., Yunus, N. M., Mydin, R. B. S., Aris, F., & Zakaria, N. A. (2026). Navigating key mutations in RBD and SARS-CoV-2 epitope classification: Enhancing antibody therapeutic development amidst evolving challenges. Asia-Pacific Journal of Molecular Biology and Biotechnology, 12. https://doi.org/10.35118/apjmbb.2026.034.2.02
Vancouver
Alexsius K, Amin IM, Yunus NM, Mydin RBS, Aris F, Zakaria NA. Navigating key mutations in RBD and SARS-CoV-2 epitope classification: Enhancing antibody therapeutic development amidst evolving challenges. Asia-Pacific Journal of Molecular Biology and Biotechnology. 2026:12. doi:10.35118/apjmbb.2026.034.2.02
BibTeX
@article{Alexsius2026,
author = {Alexsius, Kelven and Amin, Indah Mohd and Yunus, Norfatimah Mohamed and Mydin, Rabiatul Basria S.M.N. and Aris, Farizan and Zakaria, Nurul Aili},
title = {Navigating key mutations in RBD and SARS-CoV-2 epitope classification: Enhancing antibody therapeutic development amidst evolving challenges},
journal = {Asia-Pacific Journal of Molecular Biology and Biotechnology},
year = {2026},
pages = {12},
doi = {10.35118/apjmbb.2026.034.2.02}
}
EUVIMED